{"id":"https://openalex.org/W2015696027","doi":"https://doi.org/10.1002/phar.1303","title":"The Clinical Efficacy and Safety of Sodium Glucose Cotransporter\u20102 Inhibitors in Adults with Type 2 Diabetes Mellitus","display_name":"The Clinical Efficacy and Safety of Sodium Glucose Cotransporter\u20102 Inhibitors in Adults with Type 2 Diabetes Mellitus","alternate_titles":[],"publication_year":2013,"publication_date":"2013-06-06","ids":{"openalex":"https://openalex.org/W2015696027","doi":"https://doi.org/10.1002/phar.1303","mag":"2015696027","pmid":"https://pubmed.ncbi.nlm.nih.gov/23744749"},"language":"en","primary_location":{"id":"doi:10.1002/phar.1303","doi":"https://doi.org/10.1002/phar.1303","is_oa":false,"landing_page_url":"https://doi.org/10.1002/phar.1303","pdf_url":null,"source":{"id":"https://openalex.org/S122731057","display_name":"Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy","issn_l":"0277-0008","issn":["0277-0008","1875-9114"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2015696027"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5078106776","display_name":"Shawn Riser Taylor","orcid":"https://orcid.org/0000-0002-6689-3820","observed_orcids":["https://orcid.org/0000-0002-6689-3820"]},"institutions":[{"id":"https://openalex.org/I148244530","display_name":"Wingate University","ror":"https://ror.org/01yyxv878","country_code":"US","type":"education","lineage":["https://openalex.org/I148244530"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Shawn Riser Taylor","raw_affiliation_strings":["Wingate University School of Pharmacy; Hendersonville Campus; Hendersonville North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Wingate University School of Pharmacy; Hendersonville Campus; Hendersonville North Carolina","institution_ids":["https://openalex.org/I148244530"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5109482910","display_name":"Kira B. Harris","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I148244530","display_name":"Wingate University","ror":"https://ror.org/01yyxv878","country_code":"US","type":"education","lineage":["https://openalex.org/I148244530"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Kira B. Harris","raw_affiliation_strings":["Wingate University School of Pharmacy, Wingate Campus, Wingate, North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Wingate University School of Pharmacy, Wingate Campus, Wingate, North Carolina","institution_ids":["https://openalex.org/I148244530"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5078106776"],"corresponding_institution_ids":["https://openalex.org/I148244530"],"apc_list":{"value":4030,"currency":"USD","value_usd":4030},"apc_paid":null,"fwci":1.8329,"has_fulltext":false,"cited_by_count":113,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.85764411,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":94,"max":100},"biblio":{"volume":"33","issue":"9","first_page":"984","last_page":"999"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sglt2-inhibitors","display_name":"SGLT2 inhibitors","score":0.9459999799728394},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9940000176429749},{"id":"https://openalex.org/keywords/dapagliflozin","display_name":"dapagliflozin","score":0.9980000257492065},{"id":"https://openalex.org/keywords/canagliflozin","display_name":"canagliflozin","score":1.0},{"id":"https://openalex.org/keywords/empagliflozin","display_name":"empagliflozin","score":1.0},{"id":"https://openalex.org/keywords/glycosuria","display_name":"glycosuria","score":0.7770000100135803},{"id":"https://openalex.org/keywords/renal-glucose-reabsorption","display_name":"renal glucose reabsorption","score":0.8349999785423279},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.8500000238418579},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.8669999837875366},{"id":"https://openalex.org/keywords/blood-pressure-reduction","display_name":"blood pressure reduction","score":0.6570000052452087},{"id":"https://openalex.org/keywords/triglyceride-lowering","display_name":"triglyceride lowering","score":0.8450000286102295},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.9929999709129333},{"id":"https://openalex.org/keywords/adverse-effects","display_name":"adverse effects","score":0.8289999961853027},{"id":"https://openalex.org/keywords/urinary-frequency","display_name":"urinary frequency","score":0.7739999890327454},{"id":"https://openalex.org/keywords/risk-benefit-assessment","display_name":"risk-benefit assessment","score":0.6309999823570251}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.920738160610199},{"id":"https://openalex.org/C2910068830","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 Diabetes Mellitus","level":3,"score":0.7524329423904419},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5950194597244263},{"id":"https://openalex.org/C188053792","wikidata":"https://www.wikidata.org/wiki/Q3640664","display_name":"Cotransporter","level":3,"score":0.5381006002426147},{"id":"https://openalex.org/C2777451236","wikidata":"https://www.wikidata.org/wiki/Q5030940","display_name":"Canagliflozin","level":4,"score":0.5296363830566406},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4650242328643799},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.46452295780181885},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4611521065235138},{"id":"https://openalex.org/C537181965","wikidata":"https://www.wikidata.org/wiki/Q658","display_name":"Sodium","level":2,"score":0.37482020258903503},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3724173903465271},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000068896","descriptor_name":"Canagliflozin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077203","descriptor_name":"Sodium-Glucose Transporter 2 Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D001559","descriptor_name":"Benzhydryl Compounds","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D001559","descriptor_name":"Benzhydryl Compounds","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D001559","descriptor_name":"Benzhydryl Compounds","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D005960","descriptor_name":"Glucosides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D005960","descriptor_name":"Glucosides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D005960","descriptor_name":"Glucosides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013876","descriptor_name":"Thiophenes","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D013876","descriptor_name":"Thiophenes","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D013876","descriptor_name":"Thiophenes","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D051297","descriptor_name":"Sodium-Glucose Transporter 2","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1002/phar.1303","doi":"https://doi.org/10.1002/phar.1303","is_oa":false,"landing_page_url":"https://doi.org/10.1002/phar.1303","pdf_url":null,"source":{"id":"https://openalex.org/S122731057","display_name":"Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy","issn_l":"0277-0008","issn":["0277-0008","1875-9114"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","raw_type":"journal-article"},{"id":"pmid:23744749","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23744749","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacotherapy","raw_type":"Journal Article"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.905.7521","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.905.7521","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"https://www.researchgate.net/profile/Shawn_Taylor/publication/237070981_The_Clinical_Efficacy_and_Safety_of_Sodium_Glucose_Cotransporter-2_Inhibitors_in_Adults_with_Type_2_Diabetes_Mellitus/links/53fca4360cf22f21c2f3f219.pdf","raw_type":"text"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":48,"referenced_works":["https://openalex.org/W175419662","https://openalex.org/W1499452111","https://openalex.org/W1953840628","https://openalex.org/W1973240292","https://openalex.org/W1974115114","https://openalex.org/W1997018189","https://openalex.org/W2000047428","https://openalex.org/W2002760082","https://openalex.org/W2008443217","https://openalex.org/W2034495067","https://openalex.org/W2036227043","https://openalex.org/W2047922146","https://openalex.org/W2060530397","https://openalex.org/W2062351818","https://openalex.org/W2068374049","https://openalex.org/W2070579138","https://openalex.org/W2078882023","https://openalex.org/W2078992128","https://openalex.org/W2080383778","https://openalex.org/W2081276121","https://openalex.org/W2081510795","https://openalex.org/W2083214694","https://openalex.org/W2084511068","https://openalex.org/W2085047466","https://openalex.org/W2100447481","https://openalex.org/W2107146663","https://openalex.org/W2114276479","https://openalex.org/W2121367181","https://openalex.org/W2122077393","https://openalex.org/W2123984464","https://openalex.org/W2127833912","https://openalex.org/W2131135469","https://openalex.org/W2132042838","https://openalex.org/W2134855422","https://openalex.org/W2135514341","https://openalex.org/W2149185387","https://openalex.org/W2149973065","https://openalex.org/W2150424694","https://openalex.org/W2150855258","https://openalex.org/W2152211669","https://openalex.org/W2155287847","https://openalex.org/W2167984652","https://openalex.org/W2170276146","https://openalex.org/W2172193326","https://openalex.org/W2762694848","https://openalex.org/W4245367233","https://openalex.org/W4245479565","https://openalex.org/W7012063851"],"related_works":["https://openalex.org/W3012915650","https://openalex.org/W3190946148","https://openalex.org/W2607774463","https://openalex.org/W2072040765","https://openalex.org/W2290646560","https://openalex.org/W4236245991","https://openalex.org/W2261086393","https://openalex.org/W2979652934","https://openalex.org/W2061457508"],"abstract_inverted_index":{"The":[0],"use":[1],"of":[2,54,62,75,83,110,159,209],"currently":[3],"available":[4],"antihyperglycemic":[5],"agents":[6,65,180],"can":[7],"be":[8],"limited":[9],"by":[10,78],"contraindications;":[11],"cost;":[12],"renal":[13,81],"and":[14,20,29,40,57,99,108,113,132,156,165,172,176],"hepatic":[15],"dosage":[16],"adjustments;":[17],"dosing":[18],"schedules;":[19],"adverse":[21,167,186],"effects":[22,168,187],"such":[23],"as":[24,138],"gastrointestinal":[25],"upset,":[26],"weight":[27,157],"gain,":[28],"hypoglycemia.":[30],"These":[31,64],"limitations":[32],"have":[33,58,181,191],"led":[34],"the":[35,80,89,106,185,206],"pharmaceutical":[36],"industry":[37],"to":[38,50,128,161],"identify":[39],"pursue":[41],"alternative":[42],"therapies.":[43],"Sodium":[44],"glucose":[45,72,135],"cotransporter-2":[46],"(SGLT-2)":[47],"inhibitors":[48,125],"belong":[49],"a":[51,59,147,193],"new":[52],"class":[53],"diabetes":[55],"drugs":[56],"novel":[60],"mechanism":[61],"action.":[63],"are":[66,126],"unique":[67],"in":[68,149,154,195,201],"that":[69,123],"they":[70],"increase":[71],"excretion,":[73],"independent":[74],"insulin":[76],"secretion,":[77],"inhibiting":[79],"reabsorption":[82],"glucose,":[84],"inducing":[85],"glycosuria.":[86],"To":[87],"summarize":[88],"current":[90],"evidence":[91],"for":[92],"SGLT-2":[93,124,210],"inhibitor":[94,211],"therapy,":[95],"we":[96],"reviewed":[97],"abstracts":[98],"published":[100],"data":[101],"from":[102,119],"human":[103],"trials":[104,121],"evaluating":[105],"efficacy":[107],"safety":[109],"dapagliflozin,":[111],"canagliflozin,":[112],"empagliflozin":[114],"through":[115],"February":[116],"2013.":[117],"Data":[118],"these":[120,179],"suggest":[122],"able":[127],"lower":[129],"hemoglobin":[130],"A1c":[131],"fasting":[133],"blood":[134,151],"when":[136],"used":[137],"either":[139],"monotherapy":[140],"or":[141],"combination":[142],"therapy.":[143,212],"Cardiometabolic":[144],"benefits":[145],"included":[146],"reduction":[148,153],"systolic":[150],"pressure,":[152],"triglycerides,":[155],"loss":[158],"up":[160],"3":[162],"kg.":[163],"Common":[164],"serious":[166],"including":[169],"infections,":[170],"cancer,":[171],"pollakiuria":[173],"were":[174],"identified":[175],"reviewed.":[177],"Although":[178],"generally":[182],"demonstrated":[183],"efficacy,":[184],"associated":[188],"with":[189],"dapagliflozin":[190],"caused":[192],"delay":[194],"its":[196],"regulatory":[197],"approval.":[198],"Continued":[199],"research":[200],"this":[202],"area":[203],"will":[204],"determine":[205],"risk:benefit":[207],"ratio":[208]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2015696027","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":13},{"year":2018,"cited_by_count":11},{"year":2017,"cited_by_count":8},{"year":2016,"cited_by_count":11},{"year":2015,"cited_by_count":13},{"year":2014,"cited_by_count":21},{"year":2013,"cited_by_count":5}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
